ACST Stock – (NASDAQ: ACST) is actually providing an update on the use
As necessary pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX-V: ACST) is actually giving an update on the usage of the “at the market” equity of its providing plan.
As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to put into practice an “at-the market” equity offering system under which Acasti may well issue and promote from time to time its common shares having an aggregate offering price of up to seventy five dolars million through the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions reported on January 27, 2021, Acasti issued an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 zillion. The ATM Shares had been sold at prevailing market prices averaging US$1.0747 per share. No securities had been marketed throughout the facilities of the TSXV or maybe, to the expertise of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, as well as the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March 5, 2021.
The additional capital raised has strengthened Acasti’s balance sheet and can provide the Company with more freedom in its ongoing review process to check out as well as evaluate strategic options.
Approximately Acasti – ACST Stock
Acasti is actually a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescribed drugs making use of OM3 fatty acids delivered both as free fatty acids and bound-to-phospholipid esters, produced from krill oil. OM3 fatty acids have substantial clinical evidence of safety as well as efficacy for lowering triglycerides in individuals with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being formulated for individuals with severe HTG.
Forward Looking Statements – ACST Stock
Statements of this press release which are not statements of current or historical truth constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” to the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward-looking statements include known and unknown risks, uncertainties, as well as other unknown factors that might cause the actual outcomes of Acasti to be materially different from historical results and even from any future outcomes expressed or even implied by such forward-looking statements. In addition to statements which explicitly describe these types of risks as well as uncertainties, readers are urged to give some thought to statements marked with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other related expressions to be uncertain and forward-looking. People are actually cautioned not to place undue reliance on these forward looking statements, which speak simply as of the particular date of this particular press release. Forward-looking assertions in this press release include, but aren’t limited to, statements or info concerning Acasti’s strategy, future operations and its review of strategic alternatives.
The forward looking assertions contained in this press release are expressly qualified in the entirety of theirs by this alerting declaration, the “Special Note Regarding Forward-Looking Statements” section in Acasti’s newest annual report on Form 10 K and quarterly report on Form 10-Q, which are actually available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor area of Acasti’s website at www.acastipharma.com. All forward looking statements in that press release exist as of the particular date of this particular press release.
ACST Stock – Acasti doesn’t undertake to update any such forward-looking statements whether as a consequence of information that is brand new , future events or perhaps otherwise, except as called for by law. The forward-looking assertions contained herein are also subject typically to risks and assumptions as well as uncertainties that are actually discussed from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the use